Clinical Trial: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Periphera

Brief Summary: To determine the clinical response rate of everolimus in combination with bevacizumab for patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated malignant peripheral nerve sheath tumor (MPNST). To evaluate the toxicity and safety of everolimus in combination with bevacizumab in individuals with MPNST

Detailed Summary:
Sponsor: Sarcoma Alliance for Research through Collaboration

Current Primary Outcome: Evaluation of lesions for progression or response via Who criteria [ Time Frame: great than or equal to 4 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Sarcoma Alliance for Research through Collaboration

Dates:
Date Received: August 7, 2012
Date Started: September 2012
Date Completion: December 2017
Last Updated: October 12, 2016
Last Verified: October 2016